Navigation Links
Echo Therapeutics Reports Third Quarter 2007 Results
Date:11/20/2007

Completion of Strategic Acquisition Reflected in Q3 Results

FRANKLIN, Mass., Nov. 20 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE) today announced financial results for the third quarter ended September 30, 2007. For the quarter ended September 30, 2007, net loss was $8,677,000 or $.70 per share, compared to $1,390,000 or $.49 per share, for the same period in 2006. For the nine months ended September 30, 2007, net loss was $10,278,000, or $1.05 per share, compared to $4,229,000 or $1.60 per share, for the same period in 2006. Net loss for the three and nine months ended September 30, 2007 included purchased research and development of $6,556,000 in connection with the strategic acquisition of Echo Therapeutics, Inc. as described in more detail below.

Cash and short term investments totaled $2,218,000 at September 30, 2007, compared to $559,000 at December 31, 2006.

Recent Highlights

The quarter was highlighted by the merger of Sontra Medical Corporation with Echo Therapeutics, Inc. and the surviving Company's name change to Echo Therapeutics, Inc. The merger created a dual platform-enabled transdermal therapeutics and diagnostics company focused on multiple large markets for improved formulations of specialty pharmaceuticals and new applications of next generation transdermal diagnostics for diabetes management and hospital intensive care markets. Echo Therapeutics is now marked by the following key attributes and capabilities:

-- Two transdermal drug penetration technologies, with emphasis on

development and commercialization advanced reformulations of

well-established, FDA-approved products using Echo's AzoneTS dermal

penetration enhancement technology in concert with a 505(b)(2)

regulatory strategy and development of a next generation wireless,

needle-free, continuous transdermal glucose monitor system for the

diabetes home use an
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Resources Group finds that the vascular access device market in ... India and China (BRIC) was ... size of the United States market that ... growth as a result of strong economic expansion, improving access to ... Decision Resources Group,s coverage of the BRIC vascular access device market: ...
(Date:8/20/2014)... 2014 Not long ago, it was ... be performed late in the development cycle – even ... regulatory trends suggest that, like many things GxP, expectations ... recent years, multiple drug sponsors have been required by ... questions during phase I/II. It’s not only clinical trial ...
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic ... expanded its myPROpad™ ePRO tablet with the addition of ... the most widely used and well-respected Patient Reported Outcome ... EQ-5D is used during clinical trials and in other ... be used to demonstrate Health-Related Quality of Life outcomes ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 Shimadzu ... chromatography systems, Prominence-i and Nexera-i, adding to the ... Combining excellent functionality, an intuitive operating environment, and ... a more efficient workflow for conventional to ultra-high-speed ... innovative, intuitive and intelligent design so users can ...
Breaking Biology Technology:BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2EQ-5D™ Assessment Now Available for iPad 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3
... February 8 /PRNewswire-FirstCall/,-- Evotec AG (Frankfurt Stock Exchange: EVT) today announced ... & Investor Conference,in New York., Date: ... 11.45 am EST (05.45 pm ... City, The presentation slides will be available on the Evotec ...
... AND FULL YEAR 2007 FINANCIAL RESULTS, 2008 OUTLOOK AND, ... ON CONFERENCE CALL AND WEBCAST, HAYWARD, Calif., Feb. ... discuss its fourth quarter and full year,2007 financial results, ... matters related to the company,s business on Thursday, February,28, ...
... CHAPEL HILL, N.C., Feb. 7 Falling stock prices,devaluing ... market,are just a few of the symptoms of the ... all industries, it may have a deeper impact,on pharma ... with,increasing pricing and regulatory pressures and decreasing numbers of ...
Cached Biology Technology:Kosan Announces February 28, 2008 Conference Call and Webcast 2Pharmaceutical Budget and Staffing: Powerful New Metrics-Based Study 2
(Date:8/19/2014)... supermarkets to encourage healthier spending habits? A new study ... question by tracking the purchasing records in a supermarket ... the nutritional value of foods for sale. , The ... PhD, and Brian Wansink PhD, author of Slim by ... Hannaford Supermarkets in the Northeastern United States between January ...
(Date:8/19/2014)... at retail seafood counters in 10 different states ... consumers to unexpectedly high levels of mercury, a ... a fish of the same species, but from ... offense, according to new research by University of ... seafood is essential to allow consumers to choose ...
(Date:8/19/2014)... during warm phases and became extinct during cold phases, ... link between marine crocodilian diversity and the evolution of ... million years. , The research, led by Dr ... formerly from the University of Bristol, UK is published ... are ,cold-blooded, animals that mainly live in fresh waters ...
Breaking Biology News(10 mins):Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3Evolution of marine crocodilians constrained by ocean temperatures 2
... new information about a key protein,s role in the ... work could one day lead to new treatments for ... The University of Texas at Dallas, School of Behavioral ... student Francisco Garcia on a series of papers that ...
... Research!America Annual Advocacy Awards reception and dinner ... research including Senator Barbara Mikulski, D-(MD), winner of the ... other honorees: Sanjay Gupta, MD, the Emmy-Award winning chief ... of the National Library of Medicine; Margaret Foti, ...
... technology, satellite mapping, and ground-based plot surveys, a team ... of carbon stocks in remote and fragile Madagascar. The ... carbon stocks in rugged geographic regions and that this ... support conservation and climate-change mitigation under the United Nations ...
Cached Biology News:Study looks at possible link to hyper-excitability factors in epilepsy, autism and more 2Super high-resolution carbon estimates for endangered Madagascar 2
OmniSlide Heated Wash Module. 2 independent chambers with precise temperature control from ambient of 5C to 70C. Each chamber holds 1 slide rack (20 slides). Includes 2 x Wash Sleeves, 1 x Slide R...
... bioassays for interferons are cytopathic effect inhibition assays, ... Sample types include; tissue culture supernatents; serum from ... assays, one unit is defined as the quantity ... cytopathic effect of viral infection by 50%. ...
... interferons are cytopathic effect inhibition assays, also known ... include; tissue culture supernatents; serum from PK studies ... unit is defined as the quantity of interferon ... of viral infection by 50%. All ...
OmniSlide thermal Cycler for slide applications. 20 slide capacity. Humidity Chamber. Slide Rack can be transferred directly to Wash Module to avoid handling individual slides....
Biology Products: